01—Abstract
Summary
Summary of the 8-K filed March 10, 2025. Cited figures are marked; the original filing is the authoritative source.
Cencora, Inc. (COR) has filed an 8-K to disclose an update to its fiscal year 2025 financial guidance, which will be presented at the Leerink Partners Global Healthcare Conference on March 10, 2025.
The company has raised its adjusted diluted earnings per share (EPS) forecast for FY2025 to a range of $15.30 to $15.60a, an increase from the prior guidance of $15.25 to $15.55. This upward revision is attributed to continued positive momentum in the Company's core U.S. Healthcare Solutions segment during the second quarter of fiscal 2025. Importantly, this updated guidance does not incorporate any changes or expectations related to the recently completed acquisition of Retina Consultants of America, suggesting that potential impacts from this acquisition have not yet been factored into the revised EPS outlook.
Investors should note that the provided EPS is a non-GAAP measure, and the company details specific exclusions used in its calculation, such as gains from antitrust litigation, amortization of acquisition-related intangibles, and other one-time or non-recurring items. Cencora emphasizes that this non-GAAP measure is used by management for operational evaluation and performance assessment.
02—Key points
Key Highlights
- Cencora, Inc. (COR) announced an increase in its fiscal year 2025 adjusted diluted EPS guidance.
- The new FY2025 adjusted diluted EPS forecast is $15.30 - $15.60, up from the previous $15.25 - $15.55 range.
- The guidance update reflects strong performance and continued momentum in the U.S. Healthcare Solutions segment during Q2 FY2025.
- The updated guidance does NOT include any impact from the recently completed acquisition of Retina Consultants of America.
- Cencora will be presenting this information at the Leerink Partners Global Healthcare Conference on March 10, 2025.
- The disclosed EPS figure is a non-GAAP measure, excluding various one-time and non-recurring items.
- The company provides a detailed list of adjustments made to calculate adjusted diluted EPS.
03—Questions
Frequently Asked Questions
What is the main reason for Cencora's updated FY2025 guidance?
The primary driver for the upward revision in Cencora's fiscal year 2025 adjusted diluted EPS guidance is the continued positive momentum observed in its core U.S. Healthcare Solutions reportable segment during the second quarter of fiscal 2025.
Does the updated EPS guidance include the impact of the Retina Consultants of America acquisition?
No, Cencora explicitly states that the updated guidance does not reflect any change in expectations or incorporate any impact from the recently completed acquisition of Retina Consultants of America.
What is 'adjusted diluted EPS' and why is it used?
Adjusted diluted EPS is a non-GAAP financial measure that excludes certain items that management believes are not indicative of ongoing operating performance. These typically include unusual, non-operating, unpredictable, or non-cash items like gains from litigation settlements, amortization of acquisition-related intangibles, and restructuring costs. Cencora's management uses this measure for evaluating operating performance, financial planning, and incentive compensation, and believes it provides useful supplementary information to investors.
Where can investors find more details or a live webcast of the presentation?
Investors can access live webcasts and subsequent replays of the presentation from Cencora's Investor Relations website at investor.cencora.com. The company reserves the right to discontinue these replays at any time.
04—Continue